Compass Pathways PLC
NASDAQ:CMPS

Watchlist Manager
Compass Pathways PLC Logo
Compass Pathways PLC
NASDAQ:CMPS
Watchlist
Price: 4.41 USD -0.9% Market Closed
Market Cap: 301.6m USD
Have any thoughts about
Compass Pathways PLC?
Write Note

Compass Pathways PLC
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Compass Pathways PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Compass Pathways PLC
NASDAQ:CMPS
Cash from Operating Activities
-$97.4m
CAGR 3-Years
-33%
CAGR 5-Years
-58%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$160.3m
CAGR 3-Years
-147%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Operating Activities
-$145.6m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Operating Activities
-$202.6m
CAGR 3-Years
-113%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
ÂŁ2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
ÂŁ29.8m
CAGR 3-Years
-24%
CAGR 5-Years
-2%
CAGR 10-Years
-1%
No Stocks Found

Compass Pathways PLC
Glance View

Market Cap
301.7m USD
Industry
Biotechnology

Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

CMPS Intrinsic Value
2.81 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Compass Pathways PLC's Cash from Operating Activities?
Cash from Operating Activities
-97.4m USD

Based on the financial report for Dec 31, 2023, Compass Pathways PLC's Cash from Operating Activities amounts to -97.4m USD.

What is Compass Pathways PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-58%

Over the last year, the Cash from Operating Activities growth was 8%. The average annual Cash from Operating Activities growth rates for Compass Pathways PLC have been -33% over the past three years , -58% over the past five years .

Back to Top